• Vaccine-induced immunity

    is the only promising solution

    for the ongoing COVID-19 pandemic

    There is continued need for phase 2 & 3 vaccine trials to reach long-term immunity of the entire European population.




    Volunteer Registry     Site Network

  • VACCELERATE

    will be the pan-European backbone for the acceleration of phase 2 & 3 COVID-19 vaccine trials. The overall objective is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct.

  • The

    VACCELERATE

    network

    offer solutions for characteristic vaccine development issues during pandemics by closing gaps in public health knowledge and improving knowledge transfer.

    VACCELERATE amalgamates the expertise across Europe into one network to deliver strategic scientific leadership and guidance on vaccine trials in Europe.

Who we are?

VACCELERATE is a clinical research network for the coordination & conduct of COVID-19 vaccine trials. The network is comprised of academic institutions from all over Europe: The consortium is led by the University of Cologne, Germany, and currently includes 29 national partners in 18 EU-member states & 5 countries associated to the EU Horizon 2020 research programme.

VACCELERATE is funded by the European Commission's activities for future pandemic preparedness, the "HERA Incubator", an instrument that was created in analogy to United States' BARDA.

What we do!

VACCELERATE offers expertise, services, resources and solutions to speed up existing and upcoming development programmes and market authorisation for new vaccines and vaccination strategies. The network serves as a single entry-point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 & 3 trials in Europe. The network will address any research question of interest, such as vaccine efficacy in virus variants, trials in children, pregnant women, immuno-compromised patients, trials on combination of different vaccines etc. The establishment of a European volunteer registry for vaccine trials provides fast & efficient recruitment of trial participants (>29,000 volunteers in Germany, Ireland, Sweden, Turkey, Cyprus, expansion to more countries ongoing).

VACCELERATE conducts capacity mapping of new clinical trial sites & laboratories with standardised methods and protocols, and provides standardised educational measures, training and quality management for harmonised vaccine trials. It already holds information on 425 clinical trial sites in 36 European countries (EUVAP). Harmonisation of data acquisition across all network sites enables open data exchange for valid data analysis.

Facts:

  • 29 partners in 18 EU-member states and 5 countries associated to the EU Horizon 2020 research programme.
  • Coordinated by University Hospital Cologne, Germany
  • Budget of € 12 Million
  • Funded by the European Union’s Horizon 2020 research and innovation programme
  • Duration 36 months
  • Start February 2021
  • Centralised information of currently 425 vaccine trial sites in 36 European countries on their capacity to perform vaccine trials
  • Volunteer registry in Germany, Ireland, Cyprus, Turkey, Sweden (>29,000 volunteers) and ready to go in , Greece, Norway, Poland, Portugal, ))

PLATFORM BUILDING

To provide the central platform serving as single entry-point for European stakeholders in vaccine development, by:

1. Establishing a consortium of vaccine development and clinical research excellence, with decision-making and communication structures identifying needs & delivering answers and solutions to stakeholders; and
2. Offering an open strategic forum for stakeholders from industry, SME, academia, EC, member states and public health authorities.

CAPACITY MAPPING

To build and expand a network of capable clinical trial sites and laboratories prepared to kick-start high quality phase 2 & 3 COVID-19 vaccine clinical trials in EU-member states and associated countries.

EUVAP




CAPACITY BUILDING

To ensure highest-quality data output for phase 2 & 3 vaccine trials by providing educational measures to clinical trial sites and laboratories.

ACADEMY




VOLUNTEER REGISTRY

To provide access to clinical trial participants by establishing a registry for individuals volunteering to participate in phase 2 & 3 COVID-19 vaccine clinical trials.

VOLUNTEER-REGISTRY




LABORATORY ACCESS

To provide access to laboratory sites in Europe offering a comprehensive, standardised set of methods essential to phase 2 & 3 vaccine clinical trials.






SOLUTIONS for Vaccine DEVELOPMENT

Providing solutions for characteristic vaccine development issues during pandemics. To close gaps in public health knowledge on COVID-19 vaccines, and to improve knowledge transfer by providing access to harmonised data, protocols and assays that will speed up vaccine development and serve as blueprints for future pandemic preparedness.




Educational Information

We are proud to introduce to you "IDIM: Infectious Diseases In Motion", our YouTube Channel.

In this channel you find educational information related to pandemics, the Coronavirus, COVID-19, vaccination and other topics.

Visit IDIM View more Information
-->